A congressional committee is asking Gilead Sciences (GILD) to explain its pricing policies for the Truvada HIV prevention pill, the latest effort to pressure the drug maker over a medicine that has stirred controversy thanks to its high cost and federally funded research support.

In a letter sent on Wednesday to the company, the House Committee on Oversight and Reform asked for explanations for Truvada price hikes over the past decade, as well as correspondence with federal agencies about donations to the U.S. government and patents related to HIV prevention. The committee also wants data on the cost to manufacture Truvada and a follow-up pill called Descovy.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy